The U.S. Food and Drug Administration's panel of outside experts did not lend its support to Cytokinetics Inc's <a href="https://www.reuters.com/companies/CYTK.O" target="_blank">(CYTK.O)</a> heart drug, citing insufficient data on safety and efficacy.